NCT06161025 2026-01-12A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube CancerDaiichi SankyoPhase 2/3 Recruiting860 enrolled
NCT05870748 2025-09-23REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1Sutro Biopharma, Inc.Phase 2/3 Terminated600 enrolled